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S_nary EvidEnce is accumulating that the tumour-suppressor gene p53 is involved in the development of
bladder cancer. Tberefore we studied p53 mutations in 47 bladder cancrs obtained from 45 patients using
polymerase chain reaction-sing-strand conformation polymorphism (PCR-SSCP) analysis Eight out of 24
invasive tumours appeared to have a p53 mutation, while no p53 mutations were found in the uperficial
tumours. All the p53 mutations were found in grade 3 tumours. The tumours with altered p53 showed a
higher frequency of allelc loss (FAL) than the tumours without a mutation (55.8% vs 21.1%, P<0.05, x2
test). This increase in FAL suggests a correlation between p53 mutations and genetic instabilty. A significant
correlation between mutated p53 and poor survival in the whole group studied was found (P<0.001, log-rank
test). However, within the group of muscle-invasive tumours the occurrence of p53 mutations had no
additional prognostic value. Tberefore, even though p53 mutations were found in aggressie tumours, the
chnicl usefulness of its detection mso limited. Nevertheless, these results imply that p53 is involved in the
clinical behaviour of bladder cancer, its role in the progresson ofsuperficial cancer to invasive disea merits
fiuther attention.
Bladder cancer is the fifth most common cancer in the
western male population, with an annual incidence of 20
cases per 100,000. The incidence in women is lower: about
five cases per 100,000 are diagnosed annually (Raghavan et
al., 1990). Transitional cell carcinoma of the bladder is
divided into two groups: (a) superficial (pTis, pTa, pTl) and
(b) muscle invasive (pT2, pT3, pT4) disease. Most superficial
bladder cancers are associated with a good prognosis, how-
ever 10-25% clinically progress to a more aggressive state,
showing an increase in grade and/or infiltration into the
muscle layer. pTl tumours invade the lamina propria and
have a higher incidence of progression than pTa tumours,
which are confined to the urothelium. Patients with muscle-
invasive tumours usually present de novo and have a worse
prognosis. Non-random chromosomal changes have been
observed in bladder cancer, for example in cytogenetic
studies monosomy of chromosome 9 has been reported
(Gibas et al., 1984; Vanni & Scarpa, 1986; Smeets et al.,
1987; Hopman et al., 1988). Using restriction fragment length
polymorphism analysis (RFLP), allelic loss of chromosomes
9, 11 and 17 in bladder cancer has been demonstrated (Tsai
et al., 1990). Abnormalities of chromosome llp appeared to
be more frequent in invasive than in superficial tumours, and
monosomy of chromosome 9 was not correlated with grade
or stage. Loss of heterozygosity (LOH) of chromosome 17p
occurred only in high-grade (G3) tumours (Olumi et al.,
1990). The p53 gene is considered the candidate tumour-
suppressor gene on chromosome 17p, since in cancer
development one of the two alleles is frequently lost and the
remaining is mutated (Baker et al., 1989; Hollstein et al.,
1991). Recently, it has been suggested that p53 acts as a cell
cycle control protein at the level of GI to S phase transition
(Kastan et al., 1991; Livingstone et al., 1992; Yin et al.,
1992). The loss of this function may result in increased
genetic instability (Yin et al., 1992). In bladder cancer it has
been shown, by means of subcloning and sequencing of
exons 5-9, that 17p allelic loss is strongly associated with
p53 mutation (9 out of 10 cases), and out of 18 invasive
tumours 61a% had a p53 mutation (Sidransky et al., 1991).
This association of p53 mutations and invasive tumours was
confirmed in another study by using the technique of
PCR-SSCP (Fujimoto et al., 1992).
We studied p53 mutations in a group of 45 patients with
bladder cancer, using PCR-SSCP analysis. Besides a correla-
tion with grade and stage, we investigated the prognostic
significnce of p53 mutations. Since p53 mutations are
thought to be associated with genetic instability (Kastan et
al., 1991; Livingstone et al., 1992; Yin et al., 1992) we also
studied the correlation of p53 mutations and genetic insta-
bility evaluated by the frequency of allelic loss.
Matea and eods
Tumour specinens
Twenty-three snap-frozen superficial carcinomas (pTa-pTl)
and 24 muscle-invasive carcinomas (pT>2) obtained from 45
patients were analysed. Superficial tumours comprised two
recurrences of previously analysed tumours. Among the
invasive tumours, two were squamous cell carcinomas. All
the other tumours were transitional cell carcinomas.
Pathological and clinical data for the patients are sum-
marised in Table I. Genomic DNA was extracted from step-
sectioned tumours (>70% tumour cells) (Miller et al.,
1988).
PCR-SSCP analysis
PCR-SSCP analysis was performed to investigate p53 muta-
tions in exons 5-8 (Orita et al., 1989). The intron primers for
amplification of exons 5-8 were:
exon 5 S: 5'-tca ctt gtgcoc tga ctt-3'
AS: 5'-gag gaa tca gag gcc tgg-3'
exon 6 S: 5'-gag acg aca ggg ctggtt-3'
AS: 5'-gag acm cag ttg caa acc-3'
exon 7 S: 5'-cca agg cgc act ggcctc-3'
AS: 5'-gag gca agc aga ggc tgg-3'
exon 8 S: 5'-cct tac tgc ctc ttg cttc-3'
AS: 5'-tgaatc tga ggc ata act-3'
A 250 ng aliquot ofgenomic DNA was subjected to 35 cycles
of PCR (95-C, 57C, 72-C for 0.5, 2 and 1.3 min respec-
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Table I p53 mutations, clinical and pathological data for each patient
p53 mutations
Case Age Survival
no. (years) Stagelgrade EJxon/codon Amino acid change (months) Treatmeni
CGC+CTC (Arg-*Leu)
del. G-*frameshift
CAT->TAT (His+Tyr)
GAC+GTC (Asp-.Val)
GAG-+AAG (Glu+Lys)
AGT+GGT (SeroGly)
GAG->AAG (Glu+Lys)
TCA-*TGA (Ser+Stop)
31
>41
>38
>41
23
>57
>45
>64
>61
>65
52
>39
>22
>55
>58
9
>37
>55
>45
>36
>36
9
8
>36
4
6
7
3
8
>27
>66
21
10
3
2
9
32
2
5
10
5
>28
>40
29
5
TURT
TURT
TURT
TURT,C
TURT,Ct,R,Ch
TURT,Ct
TURT,BCG,Ct
TURT
TURT,BCG
TURT,BCG,Ch
TURT,Ch
TURT
TURT
TURT,BCG
TURT,Ch
TURT,Ch
TURT,BCG
TURT
TURT,Ch
TURT,Ch
TURT,Ch,BCG
TURT
TURT,Ch,Ct
TURT,R,iridium
Ct
TURT
TURT,Ch
TURT,Ch
TURT,Ch
TURT,Ch,R
TURT,Ct
TURT,R
TURT,Ct
TURT,R
TURT,R
TURT
TURT,Ct,R
TURT
TURT,R
Ct,Ch
TURT
Ct
TURT,R,Ct
TURT,Ct
TURT
aCh, chemotherapy; Ct, cystectomy; R, radiotherapy; TURT, transureteral resection of the tumour; SCC, squamous cell carcinoma; rec,
recurrent; (p), polymorphism codon 213.
tively). Exons 5, 6 and 8 were amplified in 50pLl containing:
50 mm potassium chloride 10 mM Tris-HCI (pH 8.8),
1.75 mM magnesium chloride, 2501iM deoxynucleotide
triphosphates, 10 pmol of each 5'-end labeled primer and 1.5
units of Taq polymerase (Perkin Elmer/Cetus). Exon 7 was
amplified in the same buffer containing 1.5 mM magnesium
chloride.
Five microlitres of the PCR product was diluted in 15 jil of
loading buffer (96% formamide, 20 mM EDTA, 0.05%
bromophenol blue and xylene cyanol), boiled for 3 min and
then quenched (10 min) on ice before loading (2 ,l per lane).
Each sample was applied to a 5% polyacrylamide/Tris-borate
EDTA (0.5 x) gel with and without 10% (v/v) glycerol.
Subsequently, electrophoresis was performed at room
temperature for 16 h at 6 W or 3 W respectively.
Sequence analysis
Direct sequencing of the double-stranded PCR products that
showed a shift on the SSCP gels was performed as described
previously (Kusukawa et al., 1990). Amplified PCR products
were purified using the magic PCR-preps DNA purification
system (Promega). The PCR primers were used for sequenc-
ing in the ds-DNA cycle sequencing system (Life Tech-
nologies). Electrophoresis was performed on 6% poly-
acrylamide gels containing 7 M urea.
Restrictionfragment length polymorphism
The DNA probes used were as follows: chromosome 9q,
EFD 126 (Nakamura et al., 1987); chromosome lip, H-ras
(Pulciano et al., 1982); chromosome 16q, pV962 (Mansouri et
al., 1988) and 79.2.23 (Bufton et al., 1986); chromosome 17p,
144D6 (Schwartz et al., 1988); chromosome 18q, 15.65
(Fearon & Vogelstein, 1990). RFLP analysis was performed
on the 24 patients from whom normal DNA was available
(Poddighe et al., submitted). The RFLP results were used to
determine the frequency of allelic loss (FAL), also called
fractional allelic loss (Vogelstein et al., 1989).
Statistical analysis
The Kaplan-Meier method was used to estimate survival
probability as a function of time. Differences in survival were
analysed by a log-rank test. The test was used for the
other correlations.
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Results
p53 mutations in bladder cancer
Table I summarises the results of the PCR-SSCP and
sequence analysis of the p53 gene in bladder tumours of 45
patients. Eight mutations were found in invasive tumours:
three in exon 5, one in exon 6, one in exon 7 and three in
exon 8. Seven out of the eight mutations found were point
mutations, while one appeared to be a deletion of a G.
leading to a frameshift. We found four transitions - two G to
A, one A to G and one C to T - and three transversions -
one C to G, one G to T and one A to T. In three patients
with a superficial tumour a similar shift in the SSCP pattern
of exon 6 was observed. One of these also showed loss of
heterozygosity of chromosome 17p. After sequencing it
appeared that the shift in the SSCP pattern was due to a
silent alteration of CGA to CGG at codon 213. This
polymorphism has been described previously (Mazars et al.,
1992). No mutations were found in the squamous cell car-
cinomas.
Correlation between tumour stage grade andp53 mutations
All the p53 mutations were found in grade 3 tumours, as is
shown in Table Ila (P<0.001). No mutations were found in
the group of superficial tumours, while a p53 mutation was
found in 8 out of 24 (33%) invasive tumours (P<0.001)
(Table Ilb). This is in good agreement with previous observa-
tions (Sidransky et al., 1991; Fujimoto et al., 1992).
Relation between p53 mutations andfrequency ofallelic loss
As a measure of genetic instability, we used frequency of
allelic loss (FAL). FAL was based on RFLP analysis using
probes for chromosomes 9q, llp, 16q, 17p and 18q (Table
lIla). LOH of 17p was found in seven tumours. Four
tumours showed a p53 mutation, while in two a polymor-
phism at codon 213 was found. No mutations were found in
the tumours without 17p LOH. The tumours with a p53
mutation show a FAL of 55.8%, while those without a
mutation have a FAL of 21.1% (P<0.05) (Table IIIb).
Table Ila Relationship between p53 mutation and grade
p53 mutation
Grade Negative Positive Mutations (%o
1 11 0 0
2 15 0 0
3 11 8 42
Table IIb Relationship between p53 mutation and stage
p53 mutation
Stage Negative Positive Mutations (%o
Superficial 21 0 0
Invasive 16 8 33
Table Illa Allelic loss ofchromosomes 9q. IIp, 16q, 17p and 18q and
p53 mutations in bladder tumours
RFLP analysis
Chromosomal region
Case no. Stage grade p53 mut 9q lip 16q I7p 18q
I al - 0 0 * 0 0
2 aI - 0 0 0 0 NI
3 a1 -(p) 0 0 0 0 0
4 aI - 0 0 0 0 NI
5 a1 - 0 NI 0 NI 0
6 a 1-2 - 0 0 0 0 0
7 a 1-2 -0 0 0 0
7 rec. a 1-2 -0 0 0 0
8 1 2 -(p) 0 0 0 0 ND
8 rec. a 3 -(p) 0 0 0 0 0
9 a 2 - 0 NI 0 0 0
10 a 2-3 - NI 0 0 0 NI
11 1 2 -(p) 0 0 0 0 NI
12 1 2 - * 0 0 0 NI
13 1 2 - 0 0 0 0 NI
14 1 2 - 0 0 0 0 0
15 1 2 - NI 0 0 0 0
16 1-2 1-2 - 0 NI 0 0 0
17 2 3 - 0 0 0 0 NI
18 2 3 + NI NI 0 * 0
19 >2 3 - NI NI 0 0 NI
20 >23 + * 0 0 0 0
21 3 3 - 0 0 0 NI ND
22 3 3 - NI 0 0 0 ND
23 3 3 + NI NI 0 * ND
24 4 3 + * NI 0 * 0
-, no p53 mutation; +, p53 mutation; 0, no LOH, *. LOH; NI, not
informative; ND, not determined, rec., recurrent tumour. (p), polymor-
phism at codon 213.
Correlation ofp53 mutation and survival
The survival according to p53 mutation for the whole group
of 45 patients is shown in the Kaplan-Meier curve (Figure
a). The patients with a p53 mutation survived for a shorter
period of time (X2 = 11.25, P<0.001). There was no
significant association between the presence of a p53 muta-
tion and decreased survival among patients with invasive
disease (2= 1.46, NS) (Figure lb).
Discusso
In this study, we examined mutations in the p53 gene by
PCR-SSCP analysis. We show that the occurrence of p53
mutations correlates with grade and stage, which is in con-
cordance with previous studies (Sidransky et al., 1991;
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Figue 1 Three year survival (%) of bladder cancer patients
according to the presence or absence of p53 mutations. a, All
patients (P<0.001, log-rank test). b, Patients with muscle-
invasive tumours (P = not significant).
Table IIIb Frequency of allelic loss according to p53 mutation
p53 mutation Number oftumours FAL (%J
Negative 22 21.1
Positive 4 55.8
1
4 P%^p53 MUTATIONS IN BLADDER CANCER 4"
Fujimoto et al., 1992). A p53 mutation was found in 8/24
(33%) of the invasive tumours, which were all grade 3.
The p53 tumour-suppressor gene is known to be mutated
in many types of cancer (Hollstein et al., 1991) and during
tumour progression one of the two alleles is often lost,
resulting in a reduction of growth control (Baker et al.,
1989). However, some p53 mutations are known to be
dominant negative: the proten produced by the mutated
alele has the ability to bind and inactivate the remaining
wild-type product (Vogelstein, 1990). In our study we did not
find any mutation without LOH of 17p. On the contrary, one
patient with 17p LOH had no p53 mutation. It could be that
the mutation is outside the region of the p53 gene studied or
that a second locus disnct from p53 is involved (Saxena et
al., 1992).
Wild-type p53 has been sugste to be a cell cycle control
protein, since progression from GI to S phase is often
blocked in cells expressing high levels of this protein (Kastan
et al., 1991; Livingstone et al., 1992; Yim et al., 1992). It has
been shown that cells without wild-type p53 protein fail to
show growth arrest (when subjected to conditions unfavour-
able for the S phase completion) and gene amplification
occurs (Yin et al., 1992), which can be considered a form of
genetic instability. As p53 mutations are known to occur in
bladder cancer (Sidransky et al., 1991; Fujimoto et al., 1992),
we used frequency of allelic loss as an indicator of genetic
instability (Vogestein et al., 1989). The high frequency of
allelic loss found in tumours with a p53 mutation (55.8%,
P<0.05) suggests a correlation with genetic instability. This
increase in allelic loss in tumours with a p53 mutation could
be explained by an altered GI-S cell cycle checkpoint, which
can be the result of the loss of the wild-type p53 function.
The loss of certain alleles, e.g. those harbouring tumour-
suppressor genes, could provide selective advantages during
tumour progression by generating variants with a more ag-
gressive phenotype (Fearon & Vogelstein, 1990). FAL
showed no significant correlation with grade or stage.
In breast cancer p53 mutations are inversely correlated
with survival (Allred et al., 1993). This study is the first
report investigating the prognostic signi of p53 muta-
tions in bladder cancer. The results demonstrate that p53
mutations are an unfavourable prognostic factor (P<0.001)
for the whole group studied. However, among patients with
invasive tumours there was no significant association between
the presence of a p53 mutation and a decreased survival.
Therefore, patients without a p53 mutation do not neces-
sarily have a good prognosis. There are other features that
can lead to an inactive p53 protein, such as complexing with
other proteins (Momand et al., 1992), and other genetic
events can occur that result in a poor prognosis. Epidermal
growth factor receptor (EGFR) positivity has been shown to
be associated with tumour progression and decreased survival
(Neal et al., 1990). Neal et al. also found no significant
difference between EGFR positivity and survival among
patients with invasive tumours. Furthermore, it has recently
been shown that decreased E-cadherin expression correlates
with the clinical aggressiveness of bladder cancer (Bringuier
et al., 1993).
The variable order of appearance of genetic alterations in
oncogenesis suggests that accumulation, rather than the order
of occurrence, is important for tumour progression (Fearon
& Vogelstein, 1990). The increased frequency of allelic loss
we find in the tumours with a p53 mutation can lead to
tumour progression and poorer prognosis. But, as mentioned
above, there are other mechanis which can lead to tumour
progression and these may override or bypass the function of
p53.
Recently immunohistochemical studies have shown p53
overexpression to be correlated with poor survival (Lip-
ponen, 1993; Sarkis et al., 1993). In pTl bladder tumours
Sarkis et al. (1993) found a clear correlation between nuclear
overexpression of p53 protein and disease progression. The
study of Lipponen (1993) showed a significant correlation
between p53 overexpression and decreased survival for the
entire cohort and for the muscle-invasive tumours. However
for the pTa and PT1 tumours only a trend was found. In
muscle-invasive tumours, we found no association between
p53 mutations and decreased survival. This difference stresses
again the discordance of p53 immunohistochemistry and p53
mutation analysis (Thompson et al., 1992). The discrepancy
in prognostic value for p53 mutations in superficial disease
found in the two immunohistochemical studies might be the
result of the use of different antibodies and the scoring
system used. We found no p53 mutations in superficial
tumours, which might be explained by the relative rarity of
grade 3 tumours in this group.
The results ofour study indicate that the presence of a p53
mutation is an unfavourable prognostic factor for the whole
group studied, but it has no additional prognostic value for
the group of muscle-invasive tumours. The step at which p53
mutations occur in the tumour progression cascade of blad-
der cancer is stfill unclear. In this respect grade 3 superficial
tumours deserve more attention. In general, superficial blad-
der cancer has a good prognosis, but 10-25% of these
tumours progress to an invasive stage. Therefore, the correla-
tion between prognosis and p53 mutation in this subgroup is
of particular interest.
Furthermore, the discordance ofimmunohistochemical and
p53 mutation analysis indicates that comparative analysis of
p53 mutations and overexpression of the p53 oncoprotein in
progression of the pTa and pTl tumours is necessary.
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